Sugi Predict

Sugi Predict / Compounds / SCHEMBL1661231

SCHEMBL1661231

SCHEMBL1661231

CC(C)n1nccc1-c1cc2c(=O)n(NS(C)(=O)=O)c(=O)[nH]c2cc1CF

nearest known ligand 0.45

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ USP1 O94782 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4628975 0.93 USP1 (0.31) USP1
SCHEMBL1661316 0.93 USP1 (0.32) USP1
SCHEMBL1661264 0.88 HAVCR2 (0.34) —
SCHEMBL1660573 0.86 CA12 (0.35) USP1
SCHEMBL1661015 0.86 IDH1 (0.33) USP1
SCHEMBL1660532 0.86 IDH1 (0.33) USP1
SCHEMBL1067354 0.86 USP1 (0.36) USP1
SCHEMBL12799574 0.85 USP1 (0.31) USP1
SCHEMBL1692742 0.85 CA12 (0.31) —
SCHEMBL4628060 0.80 HAVCR2 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140163050-A1 Use of 1H-quinazoline-2,4-diones JOHNS DONALD (US) 2014-06-12 — — US claimed
US-20140018376-A1 Use of 1H-Quinazoline-2,4-Diones ALLGEIER HANS (DE) 2014-01-16 — — US claimed
EP-2585070-A1 USE OF 1H-QUINAZOLINE-2,4-DIONES Novartis AG (CH) 2013-05-01 — — EP claimed
US-20130096145-A1 Use of 1H-quinazoline-2,4-diones NOVARTIS AG (CH) 2013-04-18 — — US claimed
US-20130090346-A1 Use of 1H-quinazoline-2,4-diones NOVARTIS AG (CH) 2013-04-11 — — US claimed
WO-2013036224-A1 USE OF 1H-QUINAZOLINE- 2, 4 -DIONES FOR USE IN THE PREVENTION OR TREATMENT PHOTOSENSITIVE EPILEPSY NOVARTIS AG (CH) 2013-03-14 — — WO claimed
EP-2490691-A1 USE OF 1H-QUINAZOLINE-2,4-DIONES Novartis AG (CH) 2012-08-29 — — EP claimed
US-20120122903-A1 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS NOVARTIS AG (CH) 2012-05-17 — — US claimed
WO-2011161249-A1 USE OF 1H-QUINAZOLINE-2,4-DIONES NOVARTIS AG (CH) 2011-12-29 — — WO claimed
WO-2011048150-A1 USE OF 1H-QUINAZOLINE-2,4-DIONES NOVARTIS AG (CH) 2011-04-28 — — WO claimed
US-20140163050-A1 Use of 1H-quinazoline-2,4-diones JOHNS DONALD (US) 2014-06-12 — — US disclosed
US-20140163050-A1 Use of 1H-quinazoline-2,4-diones JOHNS DONALD (US) 2014-06-12 — — US disclosed
US-20140018376-A1 Use of 1H-Quinazoline-2,4-Diones ALLGEIER HANS (DE) 2014-01-16 — — US disclosed
US-20140018376-A1 Use of 1H-Quinazoline-2,4-Diones ALLGEIER HANS (DE) 2014-01-16 — — US disclosed
US-20130296332-A1 1H-QUINAZOLINE-2,4-DIONES NOVARTIS AG (CH) 2013-11-07 — — US disclosed
US-20080153836-A1 N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders NOVARTIS AG (CH) 2008-06-26 — — US disclosed
US-20080153836-A1 N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders NOVARTIS AG (CH) 2008-06-26 — — US disclosed
US-20080153836-A1 N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders NOVARTIS AG (CH) 2008-06-26 — — US disclosed
EP-1871749-A1 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS Novartis AG (US) 2008-01-02 — — EP disclosed
WO-2006108591-A1 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS NOVARTIS AG (CH) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090346-A1 Use of 1H-quinazoline-2,4-diones GRIK2, GRIK1, GRIK4 USP1 2678/4885
US-20130096145-A1 Use of 1H-quinazoline-2,4-diones GRM1, GRIK2, GRIK1 USP1 1693/4885
US-20140018376-A1 Use of 1H-Quinazoline-2,4-Diones GRIK1, GRIK2, GRIK4 USP1 1392/4885
US-20140163050-A1 Use of 1H-quinazoline-2,4-diones GRIK2, GRIK1, GRIK4 USP1 2678/4885
US-20120122903-A1 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS CLN6, GBA1, GBA2 USP1 1239/4885
US-20080153836-A1 N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders GRIN2A, GRIN1, GRIN2D USP1 3796/4885
US-20130296332-A1 1H-QUINAZOLINE-2,4-DIONES CYP1A2, QDPR, CYP3A7 USP1 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.